NRx Pharmaceuticals: $5M Boost for NRX-101 Drug

NRx Pharmaceuticals Receives $5 Million Milestone Payment for Development of NRX-101 Drug Candidate

NRx Pharmaceuticals, Inc. has reached a significant milestone in its partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd., receiving a $5 million payment that will support the development of its drug candidate NRX-101. This milestone payment will contribute to NRX-101’s progress through a phase 2 meeting with the U.S. Food and Drug Administration (FDA). In return, Alvogen and Lotus will receive 4.1 million warrants to purchase NRx Pharmaceuticals’ common stock. The partnership is set to receive an additional $4 million after a positive outcome from the phase 2 meeting.